These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 14818479)

  • 1. Experimental physiological studies with lysergic acid diethylamide (LSD-25).
    FORRER GR; GOLDNER RD
    AMA Arch Neurol Psychiatry; 1951 May; 65(5):581-8. PubMed ID: 14818479
    [No Abstract]   [Full Text] [Related]  

  • 2. [Experimental LSD poisoning and its relation to schizophrenia. Observations on 2 borderline cases of neurosis and schizophrenia treated by repeated administration of LSD].
    MANZINI B; SARAVAL A
    Riv Sper Freniatr Med Leg Alien Ment; 1960 Sep; 84():589-618. PubMed ID: 13766357
    [No Abstract]   [Full Text] [Related]  

  • 3. THE FIGURAL AFTER-EFFECT AND LYSERGIC ACID DIETHYLAMIDE (LSD-25).
    KELM H; JENSEN SE; RAMSAY RW
    J Nerv Ment Dis; 1963 Dec; 137():557-60. PubMed ID: 14087675
    [No Abstract]   [Full Text] [Related]  

  • 4. Autistic schizophrenic children. An experiment in the use of d-lysergic acid diethylamide (LSD-25).
    FREEDMAN AM; EBIN EV; WILSON EA
    Arch Gen Psychiatry; 1962 Mar; 6():203-13. PubMed ID: 13894863
    [No Abstract]   [Full Text] [Related]  

  • 5. Studies in the effects of lysergic acid diethylamide (LSD-25); visual perception of verticality in schizophrenic and normal adults.
    LIEBERT RS; WAPNER S; WERNER H
    AMA Arch Neurol Psychiatry; 1957 Feb; 77(2):193-201. PubMed ID: 13393877
    [No Abstract]   [Full Text] [Related]  

  • 6. Studies in the effect of lysergic acid diethylamide (LSD-25): self- and object-size perception in schizophrenics and normal adults.
    LIEBERT RS; WERNER H; WAPNER S
    AMA Arch Neurol Psychiatry; 1958 May; 79(5):580-4. PubMed ID: 13519960
    [No Abstract]   [Full Text] [Related]  

  • 7. Cross tolerance between D-2-brom-lysergic acid diethylamide (BOL-148) and the D-diethylamide of lysergic acid (LSD-25).
    ISBELL H; MINER EJ; LOGAN CR
    Psychopharmacologia; 1959 Nov; 1():109-16. PubMed ID: 14405871
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison of phencyclidine hydrochloride (Sernyl) with other drugs. Simulation of schizophrenic performance with phencyclidine hydrochloride (Sernyl), lysergic acid diethylamide (LSD-25), and amobarbital (Amytal) sodium; II. Symbolic and sequential thinking.
    COHEN BD; ROSENBAUM G; LUBY ED; GOTTLIEB JS
    Arch Gen Psychiatry; 1962 May; 6():395-401. PubMed ID: 13880223
    [No Abstract]   [Full Text] [Related]  

  • 9. Lysergic acid diethylamide (LSD-25) antagonists. II. Development of tolerance in man to LSD-25 by prior administration of MLD-41 (1-methyl-d-lysergic acid diethylamide).
    ABRAMSON HA; SKLAROFSKY B; BARON MO; FREMONT-SMITH N
    AMA Arch Neurol Psychiatry; 1958 Feb; 79(2):201-7. PubMed ID: 13497364
    [No Abstract]   [Full Text] [Related]  

  • 10. THE SUBJECTIVE EXPERIENCE OF TIME DURING LYSERGIC ACID DIETHYLAMIDE (LSD-25) INTOXICATION.
    KENNA JC; SEDMAN G
    Psychopharmacologia; 1964 Mar; 5():280-8. PubMed ID: 14143340
    [No Abstract]   [Full Text] [Related]  

  • 11. Enzymic formation of dehydrogenated and hydroxylated metabolites from lysergic acid diethylamide by rat liver microsomes.
    Inoue T; Niwaguchi T; Murata T
    Xenobiotica; 1980 May; 10(5):343-8. PubMed ID: 7415216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic trial of lysergic Acid diethylamide (LSD) and thioridazine in chronic schizophrenia.
    Shirvaikar RV; Kelkar YW
    Neurol India; 1966; 14(2):97-101. PubMed ID: 5330728
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of autistic schizophrenic children with LSD-25 and UML-491.
    BENDER L; GOLDSCHMIDT L; SANKAR DV
    Recent Adv Biol Psychiatry; 1961; 4():170-9. PubMed ID: 13867084
    [No Abstract]   [Full Text] [Related]  

  • 14. Hyperthermic effects of D-lysergic acid diethylamide (LSD) and its derivatives in rabbits and rats.
    Hashimoto H; Hayashi M; Nakahara Y; Niwaguchi T; Ishii H
    Arch Int Pharmacodyn Ther; 1977 Aug; 228(2):314-21. PubMed ID: 303504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual actions of lysergic acid diethylamide tartrate (LSD), 2-bromo-D-lysergic acid diethylamide bitartrate (BOL) and methysergide on dorsal root potentials evoked by stimulation of raphe nuclei.
    Larson AA; Chinn C; Proudfit HK; Anderson EG
    J Pharmacol Exp Ther; 1981 Apr; 217(1):99-104. PubMed ID: 6110778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 'Schizophrenia' produced by LSD-25.
    BOLTON WB
    Nurs Times; 1962 Jan; 58():22-4. PubMed ID: 13870860
    [No Abstract]   [Full Text] [Related]  

  • 17. Unsurmountable antagonism of brain 5-hydroxytryptamine2 receptors by (+)-lysergic acid diethylamide and bromo-lysergic acid diethylamide.
    Burris KD; Sanders-Bush E
    Mol Pharmacol; 1992 Nov; 42(5):826-30. PubMed ID: 1359397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Studies on the problem of schizophrenia. IV. Distribution of C-14-radioactive lysergic acid diethylamide (C-14-LSD 25) in the animal organism].
    ARNOLD OH; HOFMANN G; LEUPOLD-LOWENTHAL H
    Wien Z Nervenheilkd Grenzgeb; 1958; 15(1-4):15-27. PubMed ID: 13604283
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of mescaline and lysergic acid (d-LSD-25).
    HOCH PH; CATTELL JP; PENNES HH
    Am J Psychiatry; 1952 Feb; 108(8):579-84. PubMed ID: 14903183
    [No Abstract]   [Full Text] [Related]  

  • 20. Psychopharmacological studies of lysergic acid diethylamide (LSD-25) intoxication; effects of premedication with BOL-128 (2-bromo-d-lysergic acid diethylamide), mescaline, atropine, amobarbital, and chlorpromazine.
    CLARK LD; BLISS EL
    AMA Arch Neurol Psychiatry; 1957 Dec; 78(6):653-5. PubMed ID: 13478222
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.